Evidence map›Paper›PMID 25443792›Full record

ArticleBiomaterials2015

[Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction.

Vahid Serpooshan, Senthilkumar Sivanesan, Xiaoran Huang, Morteza Mahmoudi, Andrey V Malkovskiy, Mingming Zhao, Mohammed Inayathullah, Dhananjay Wagh, Xuexiang J Zhang, Scott Metzler and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Targeted delivery of peptide functionalized nanoparticles for ameliorating myocardial infarction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Vahid SerpooshanStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Senthilkumar SivanesanBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xiaoran HuangBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Morteza MahmoudiStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA; Biomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Andrey V MalkovskiyBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mingming ZhaoStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA.
Mohammed InayathullahBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dhananjay WaghBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xuexiang J ZhangBiomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA.
Scott MetzlerStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA.
Daniel BernsteinStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Pilar Ruiz-LozanoStanford University, Department of Pediatrics, 300 Pasteur Dr., Stanford, CA 94305, USA; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jayakumar RajadasStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Biomaterials and Advanced Drug Delivery Laboratory, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: jayraja@stanford.edu.
Stanford University · USStanford Medicine · USCardiovascular Institute of the South · US

Funding

Training in Myocardial Biology at Stanford (TIMBS)T32HL094274 · NHLBI · STANFORD UNIVERSITY · PI Euan A Ashley, Daniel Bernstein · 2010 to 2026
$5.0M
GENETIC ABLATION OF EPICARDIAL FUNCTION IN THE MOUSER01HL065484 · NHLBI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RUIZ-LOZANO, PILAR · 2002 to 2012
$3.7M
Integrated Strategies for Novel Treatment of Myocardial IschemiaR01HL095571 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2010 to 2014
$2.0M
Genetic Rescue of Retinoid-Induced DysfunctionR01HL086879 · NHLBI · STANFORD UNIVERSITY · PI RUIZ-LOZANO, PILAR · 2009 to 2013
$1.7M
Genetic Ablation of Epicardial Function in the MouseR56HL065484 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUIZ-LOZANO, PILAR · 2007 to 2007
$478k
NHLBI NIH HHS HL086879NHLBI NIH HHS HL65484NHLBI NIH HHS R01 HL065484NHLBI NIH HHS R01 HL086879NHLBI NIH HHS R01 HL095571NHLBI NIH HHS R56 HL065484NHLBI NIH HHS T32 HL094274
6 · The paper itself

Abstract

Nanoparticle-mediated sustained delivery of therapeutics is one of the highly effective and increasingly utilized applications of nanomedicine. Here, we report the development and application of a drug delivery system consisting of polyethylene glycol (PEG)-conjugated liposomal nanoparticles as an efficient in vivo delivery approach for [Pyr1]-apelin-13 polypeptide. Apelin is an adipokine that regulates a variety of biological functions including cardiac hypertrophy and hypertrophy-induced heart failure. The clinical use of apelin has been greatly impaired by its remarkably short half-life in circulation. Here, we investigate whether [Pyr1]-apelin-13 encapsulation in liposome nanocarriers, conjugated with PEG polymer on their surface, can prolong apelin stability in the blood stream and potentiate apelin beneficial effects in cardiac function. Atomic force microscopy and dynamic light scattering were used to assess the structure and size distribution of drug-laden nanoparticles. [Pyr1]-apelin-13 encapsulation in PEGylated liposomal nanocarriers resulted in sustained and extended drug release both in vitro and in vivo. Moreover, intraperitoneal injection of [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrated a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction. We concluded that this engineered nanocarrier system can serve as a delivery platform for treating heart injuries through sustained bioavailability of cardioprotective therapeutics.

Indexed as

Drug Delivery SystemsPressureAnimalsDrug CarriersElectrocardiographyHeartIntercellular Signaling Peptides and ProteinsLightLiposomesMiceMicroscopy, Atomic ForceNanoparticlesParticle SizeScattering, Radiationapelin-13 peptideDrug CarriersIntercellular Signaling Peptides and ProteinsLiposomesHypertrophyLiposomal encapsulationNanocarrier[Pyr1]-Apelin-13Sustained releaseTAC

Identifiers

PMID25443792
PMCPMC5555682
OpenAlexW2073164220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.